capital raise

SpaceX targets June 2026 IPO at $1.75 trillion valuation, raising $50-75 billion. Cross-company synergies with Tesla could drive growth in robotics and energy storage.

Blue Moon Metals closes C$4.8M financing from Hartree Partners to develop five brownfield polymetallic projects, subject to TSX Venture Exchange approval.

Precision components maker $ELMT completes $125.5M IPO at $14/share, with full underwriter option exercised. Plans debt reduction and working capital.

Wearable Devices ($WLDS) raises $5M through warrant agreement with institutional investor, exercising 2.9M shares at $1.73 each amid 83% annual decline.

Maze Therapeutics prices $150M offering at $23.50/share, securing funding through 2029 for kidney disease and PKU programs.

Faraday Future secures $45M in convertible debt through Univest Securities at 9% interest with conversion features tied to stock performance.

Lucid appoints new CEO, raises $1.05B from PIF and Uber, posts record deliveries, but accelerating cash burn and dilution threaten viability through 2027.

Wearable Devices raises $5M via warrant inducement, issuing lower-priced new warrants to accelerate institutional investor exercises; closing expected April 2026.

Applied Digital posts 139% revenue growth to $127M on AI infrastructure demand, but carries $2.15B debt at 6.75% interest amid rapid expansion.

Revolution Medicines closes $2.2B concurrent offerings, including equity and convertible notes, to accelerate drug development and commercialization.

Trevi Therapeutics raises $150M via stock offering at $13/share to fund development of Haduvio for idiopathic pulmonary fibrosis-related cough.

Trevi Therapeutics prices $150M stock offering at $13/share, raising capital for Haduvio development across chronic cough indications.

Genius Group closes $8M registered direct offering, acquiring 9.9% stake in Jewel Financial to support stablecoin and digital asset ambitions.

MeiraGTx reacquires J&J's eye disease drug bota-vec for $25M, raises $100M in funding, targeting 2027 launch. Stock falls 15.8%.

Revolution Medicines raises $2.0 billion via 10.56M shares at $142/share and $500M convertible notes for R&D and commercialization.

Spyre Therapeutics prices $403M stock offering at $62/share with 6.5M shares, expected to close April 16, 2026. Prominent underwriters include Goldman Sachs and Jefferies.

Allogene prices 87.5M shares at $2.00 each, raising $175M gross proceeds for clinical trials and R&D operations.

TeraWulf raises $900M via upsized stock offering to fund Kentucky data center expansion, debt repayment, and future acquisitions, closing April 2026.

RENX delivered $8.2M revenue, beating guidance by 17% in first full operating year. Equipment delivery and $6M funding secured for expansion.

Washington Trust posted $60.8M Q4 loss from balance sheet restructuring but raised $70.5M capital. Adjusted earnings of $10.4M and NIM improvement expected.